CM
PCVX icon

Castleark Management’s Vaxcyte PCVX Stock Holding History

Castleark Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,360
Closed -$4.29M – 326
2024
Q4 		$4.29M Sell
52,360
-2,260
-4% -$224K 0.15% 147
2024
Q3 		$6.24M Buy
54,620
+10,930
+25% +$985K 0.25% 91
2024
Q2 		$3.3M Sell
43,690
-31,350
-42% -$2.13M 0.13% 148
2024
Q1 		$5.13M Sell
75,040
-10,220
-12% -$708K 0.21% 113
2023
Q4 		$5.35M Buy
85,260
+28,630
+51% +$1.49M 0.24% 101
2023
Q3 		$2.89M Sell
56,630
-12,370
-18% -$610K 0.15% 144
2023
Q2 		$3.45M Buy
+69,000
New +$3.27M 0.16% 139

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Castleark Management's PCVX Position: Q1 2025 in Review

Castleark Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 52,360 shares — an estimated $4.29M sold.

Castleark Management first reported a position in PCVX in Q2 2023 and held it in 7 quarters. The position peaked at $6.24M in Q3 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

  • Castleark Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
  • Castleark Management sold 52,360 Vaxcyte shares in Q1 2025, an estimated $4.29M.
  • Castleark Management first reported a position in Vaxcyte in Q2 2023 and held it in 7 quarters.
  • Castleark Management's Vaxcyte position peaked at $6.24M in Q3 2024.
  • 315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Castleark Management's 13F filing for Q1 2025, filed 15 May 2025.